Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, enhancing treatment efficacy and inducing programmed cell death. A novel ...

Panelists discuss how IDH inhibitors, particularly ivosidenib combined with azacitidine, represent potentially the greatest ...

Q3 2025 Management View James Dentzer, President and CEO, emphasized continued progress in the TakeAim Lymphoma study evaluating emavusertib in combination with ibrutinib in primary CNS lymphoma ...

The Investment Adviser Association and the Investment Company Institute voiced support for the two-year postponement, citing a need for tailored anti-money laundering requirements.

M2T-CD33 (LTI-214) has received FDA orphan drug designation, offering incentives like tax credits and market exclusivity for AML treatment. The treatment targets CD33, a glycoprotein present in 90% of ...

Bank-fintech partnerships have transformed the financial services landscape, creating new opportunities and challenges for traditional banking institutions and innovative technology companies alike.